The past, present and future perspectives of matrix metalloproteinase inhibitors

Kang Li, Franklin R. Tay, Cynthia Kar Yung Yiu

Research output: Contribution to journalReview article

Abstract

Matrix metalloproteinases (MMPs) are a large family of enzymes that degrade the extracellular matrix (ECM). Under pathologic conditions, overexpression of MMPs or insufficient control by tissue inhibitors of MMPs (TIMPs) results in the dysregulation of tissue remodeling and causes a variety of diseases such as encephalomyelitis, rheumatoid arthritis, Alzheimer's disease and tumors. Therefore, the high affinity of MMPs for biomolecules renders them attractive targets for inhibition when homeostasis breaks down in the ECM. There are 4 generations of MMP inhibitors (MMPIs), ranging from small molecules or peptides to antibodies and protein-engineered inhibitors of metalloproteinase. Although a plethora of MMPIs has been synthesized, most of them have failed in clinical trials or are still in the laboratory stage of development. The present review summarizes the development of MMPIs, their associated problems and discusses future directions for the development of the future generations of MMPIs.

Original languageEnglish (US)
Article number107465
JournalPharmacology and Therapeutics
Volume207
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Matrix Metalloproteinase Inhibitors
Matrix Metalloproteinases
Extracellular Matrix
Encephalomyelitis
Tissue Inhibitor of Metalloproteinases
Social Responsibility
Metalloproteases
Rheumatoid Arthritis
Alzheimer Disease
Homeostasis
Clinical Trials
Peptides
Antibodies
Enzymes
Neoplasms
Proteins

Keywords

  • Inhibitor
  • MMP
  • MMPI
  • Matrix metalloproteinase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The past, present and future perspectives of matrix metalloproteinase inhibitors. / Li, Kang; Tay, Franklin R.; Yiu, Cynthia Kar Yung.

In: Pharmacology and Therapeutics, Vol. 207, 107465, 03.2020.

Research output: Contribution to journalReview article

@article{349b7b73048540f0a1bee4e8ef99ee2e,
title = "The past, present and future perspectives of matrix metalloproteinase inhibitors",
abstract = "Matrix metalloproteinases (MMPs) are a large family of enzymes that degrade the extracellular matrix (ECM). Under pathologic conditions, overexpression of MMPs or insufficient control by tissue inhibitors of MMPs (TIMPs) results in the dysregulation of tissue remodeling and causes a variety of diseases such as encephalomyelitis, rheumatoid arthritis, Alzheimer's disease and tumors. Therefore, the high affinity of MMPs for biomolecules renders them attractive targets for inhibition when homeostasis breaks down in the ECM. There are 4 generations of MMP inhibitors (MMPIs), ranging from small molecules or peptides to antibodies and protein-engineered inhibitors of metalloproteinase. Although a plethora of MMPIs has been synthesized, most of them have failed in clinical trials or are still in the laboratory stage of development. The present review summarizes the development of MMPIs, their associated problems and discusses future directions for the development of the future generations of MMPIs.",
keywords = "Inhibitor, MMP, MMPI, Matrix metalloproteinase",
author = "Kang Li and Tay, {Franklin R.} and Yiu, {Cynthia Kar Yung}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.pharmthera.2019.107465",
language = "English (US)",
volume = "207",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The past, present and future perspectives of matrix metalloproteinase inhibitors

AU - Li, Kang

AU - Tay, Franklin R.

AU - Yiu, Cynthia Kar Yung

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Matrix metalloproteinases (MMPs) are a large family of enzymes that degrade the extracellular matrix (ECM). Under pathologic conditions, overexpression of MMPs or insufficient control by tissue inhibitors of MMPs (TIMPs) results in the dysregulation of tissue remodeling and causes a variety of diseases such as encephalomyelitis, rheumatoid arthritis, Alzheimer's disease and tumors. Therefore, the high affinity of MMPs for biomolecules renders them attractive targets for inhibition when homeostasis breaks down in the ECM. There are 4 generations of MMP inhibitors (MMPIs), ranging from small molecules or peptides to antibodies and protein-engineered inhibitors of metalloproteinase. Although a plethora of MMPIs has been synthesized, most of them have failed in clinical trials or are still in the laboratory stage of development. The present review summarizes the development of MMPIs, their associated problems and discusses future directions for the development of the future generations of MMPIs.

AB - Matrix metalloproteinases (MMPs) are a large family of enzymes that degrade the extracellular matrix (ECM). Under pathologic conditions, overexpression of MMPs or insufficient control by tissue inhibitors of MMPs (TIMPs) results in the dysregulation of tissue remodeling and causes a variety of diseases such as encephalomyelitis, rheumatoid arthritis, Alzheimer's disease and tumors. Therefore, the high affinity of MMPs for biomolecules renders them attractive targets for inhibition when homeostasis breaks down in the ECM. There are 4 generations of MMP inhibitors (MMPIs), ranging from small molecules or peptides to antibodies and protein-engineered inhibitors of metalloproteinase. Although a plethora of MMPIs has been synthesized, most of them have failed in clinical trials or are still in the laboratory stage of development. The present review summarizes the development of MMPIs, their associated problems and discusses future directions for the development of the future generations of MMPIs.

KW - Inhibitor

KW - MMP

KW - MMPI

KW - Matrix metalloproteinase

UR - http://www.scopus.com/inward/record.url?scp=85076962259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076962259&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2019.107465

DO - 10.1016/j.pharmthera.2019.107465

M3 - Review article

AN - SCOPUS:85076962259

VL - 207

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

M1 - 107465

ER -